Two Sigma Advisers
ANRO icon

Two Sigma Advisers’s Alto Neuroscience ANRO Stock Holding History

Two Sigma Advisers’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-160,100
Closed -$2.85M – 2227
2025
Q4 		$2.85M Buy
160,100
+10,200
+7% +$128K 0.01% 1045
2025
Q3 		$603K Buy
149,900
+67,700
+82% +$224K ﹤0.01% 1691
2025
Q2 		$181K Buy
82,200
+67,900
+475% +$162K ﹤0.01% 2138
2025
Q1 		$30.9K Buy
+14,300
New +$51.2K ﹤0.01% 2342

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers's ANRO Position: Q1 2026 in Review

Two Sigma Advisers sold out of Alto Neuroscience (ANRO) in Q1 2026, closing a stake of 160,100 shares — an estimated $2.85M sold.

Two Sigma Advisers first reported a position in ANRO in Q1 2025 and held it in 4 quarters. The position peaked at $2.85M in Q4 2025. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Two Sigma Advisers reported no remaining Alto Neuroscience position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 160,100 Alto Neuroscience shares in Q1 2026, an estimated $2.85M.
  • Two Sigma Advisers first reported a position in Alto Neuroscience in Q1 2025 and held it in 4 quarters.
  • Two Sigma Advisers's Alto Neuroscience position peaked at $2.85M in Q4 2025.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.